Cholera Vaccines Market Was Valued At Over USD 550.8 Million In 2015 And Is Expected To Grow At A CAGR Of 9.7% From 2016 To 2024

Cholera vaccines market size to reach $1.25 billion by 2024
“The global cholera vaccines market was valued at over USD 550.8 million in 2015
and is expected to grow at a CAGR of 9.7% from 2013 to 2024. The presence of wide
range of promising vaccine candidates in the pipeline is anticipated to accentuate
growth of the cholera vaccines market over the forecast period”
Global cholera vaccines market is expected to reach over USD 1.25 billion by
2024, according to a new report by Grand View Research, Inc. The presence of wide
range of promising vaccine candidates in the pipeline is anticipated to accentuate
growth of the cholera vaccines market over the forecast period. In July 2016, Valneva
SE has announced completion of phase II clinical trial for Clostridium difficile vaccine
candidate. Moreover, a large number of government organizations working toward
spreading awareness about immunization against the fatal diseases, such as cholera,
are expected to boost the market growth. For instance, UNICEF is involved in provision
of funding for the cholera immunization initiatives taken up by the governments of
highly cholera prominent countries, such as Kenya and Iraq.
Follow Us:
Detailed Research Report available at:
http://www.grandviewresearch.com/industry-analysis/cholera-vaccines-market
Further Key Findings from the Study Suggest:

Dukoral was the first oral cholera vaccine to get approval in the European Union
during the year 2004. This is a drinkable dosage form, which is recommended
especially for travelers. Immunization requires 2 doses of the formulation that
provides up to 3 months of protection against the target disease.

Shanchol was the first vaccine that was licensed and developed with support
from Gates Foundation. This molecule was produced by Shantha Biotechnics
and made available in India during 2009.

Vaxchora is the recently (i.e., 2016) launched single dose, live attenuated
formulation that is the only approved cholera vaccine in the U.S. This product
segment is expected to reach over USD 290 million till 2024.

Europe dominated the market in terms of revenue with over USD 203.27 million
in 2015mainly due to the availability of approved cholera vaccines such as
Dukoral and Shanchol coupled with extensive research and development
activities and the existence of key participants of the industry in this region

Introduction of first cholera vaccine during 2016 in the U.S. is expected to be the
major factor for the boost in growth of North American cholera market with a
fastest CAGR of over 12% during the forecast period.

Asia Pacific region is expected to follow this high market growth with a CAGR of
over 10% from 2016 to 2024 attributable to the growing target population base
with high unmet clinical needs.

Moreover, government support in the Asia Pacific region is expected to drive the
market growth. Major regulatory authorities for regulation of immunization in Asia
Pacific include State Food and Drug Administration, Pharmaceutical and Medical
Follow Us:
Safety Bureau, Drugs Controller General of India, etc. These authorities maintain
easy availability of safe and cost-effective cholera vaccines in this region, due to
high frequency of epidemics.

Some leading players in this market are, Valneva, PaxVax, and Shantha
Biotechnics Limited. New entrants in the market, such as Valneva and Celldex
Therapeutics, Inc. are involved in the research and development of promising
target disease immunization molecules.
Read our blog on healthcare industry:
http://www.grandviewresearch.com/blogs/healthcare
Table of content of global cholera vaccines market research report:
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 Company Market Share Analysis : Methodology
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends & Scope
4.1 Market Segmentation & scope
4.2 Market size and growth prospects
4.2.1 Market driver analysis
Follow Us:
4.2.1.1 Rise in importance of immunization across the globe
4.2.1.2 High predominance of cholera
4.2.1.3 Technology advancements in the types of vaccines
4.2.1.4 Other drivers
4.2.2 Market restraint analysis
4.2.2.1 Cost of immunization
4.2.2.2 Lack of healthcare infrastructure
4.3 Penetration & growth prospect mapping
4.4 Cholera Vaccines - SWOT Analysis, by Factor (Political & legal,
Economic and Technological)
4.5 Industry Analysis - Porter’s
Chapter 5 Market Categorization 1: Cholera Vaccines Product Estimates & Trend
Analysis
5.1 Cholera Vaccines Market: Product Movement Analysis
5.2 Dukoral
5.2.1 Dukoral market, 2013 - 2024 (USD Million)
5.3 Shanchol
5.3.1 Shanchol market, 2013 - 2024 (USD Million)
Follow Us:
5.4 Vaxchora
5.4.1 Vaxchora market, 2013 - 2024 (USD Million)
5.5 Others
5.5.1 Other cholera vaccines market, 2013 - 2024 (USD Million)
Chapter 6 Market Categorization 3: Regional Estimates & Trend Analysis, by
Product
6.1 Cholera Vaccines Market Share by Region, 2015 & 2024
6.2 North America
6.2.1 U.S.
6.2.2 Canada
6.3 Europe
6.3.1 Germany
6.3.2 UK
6.4 Asia Pacific
6.4.1 China
6.4.2 India
6.5 Latin America
Follow Us:
6.5.1 Brazil
6.6 MEA
6.6.1 South Africa
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Company Profiles
7.3 Merck & Co. Inc
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Product benchmarking
7.3.4 Strategic initiatives
7.4 GlaxoSmithKline plc (GSK)
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Product benchmarking
7.4.4 Strategic initiatives
7.5 SANOFI
Follow Us:
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Product benchmarking
7.5.4 Strategic initiatives
7.6 Pfizer, Inc.
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Product benchmarking
7.6.4 Strategic initiatives
7.7 Takeda Pharmaceutical Company Limited
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Product benchmarking
7.7.4 Strategic initiatives
7.8 Astellas Pharma, Inc.
7.8.1 Company overview
7.8.2 Financial performance
Follow Us:
7.8.3 Product benchmarking
7.8.4 Strategic initiatives
7.9 Emergent BioSolutions, Inc.
7.9.1 Company overview
7.9.2 Financial performance
7.9.3 Product benchmarking
7.9.4 Strategic initiatives
7.10 AstraZeneca
7.10.1 Company overview
7.10.2 Financial performance
7.10.3 Product benchmarking
7.10.4 Strategic initiatives
7.11 Mitsubishi Tanabe Pharma Corporation
7.11.1 Company overview
7.11.2 Financial performance
7.11.3 Product benchmarking
7.11.4 Strategic initiatives
Follow Us:
About Grand View Research, Inc.:
Grand View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The company
provides syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, the company offers
market intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: [email protected]
Web – http://www.grandviewresearch.com/
Follow Us:

Global cholera vaccines market is expected to reach over USD 1.25 billion by 2024, according to a new report by Grand View Research, Inc. The presence of wide range of promising vaccine candidates in the pipeline is anticipated to accentuate growth of the cholera vaccines market over the forecast period. In July 2016, Valneva SE has announced completion of phase II clinical trial for Clostridium difficile vaccine candidate. Click here - http://www.grandviewresearch.com/industry-analysis/cholera-vaccines-market

Download Report